Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Polymyositis and dermatomyositis classification

Introduction

Overview

Overview

Polymyositis and dermatomyositis is one of the subtypes of idiopathic inflammatory myopathy. The 2017 European League Against Rheumatism and American College of Rheumatology (EULAR/ACR) classified idiopathic inflammatory myopathy into 6 subtypes including polymyositis, dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathies (IMNM), amyopathic dermatomyositis, and juvenile dermatomyositis.

Classification

Classification

  • Polymyositis and dermatomyositis is one of the subtypes of idiopathic inflammatory myopathy.[1][2]
  • The 2017 European League Against Rheumatism and American College of Rheumatology (EULAR/ACR) classified idiopathic inflammatory myopathy into 6 subtypes:[3][4][5]
    • Polymyositis
    • Dermatomyositis
    • Inclusion body myositis
    • Immune-mediated necrotizing myopathies (IMNM)
    • Amyopathic dermatomyositis
    • Juvenile dermatomyositis
References

References

  1. ↑ Bronner, I. M. (2009). Polymyositis and dermatomyositis: classification, risk factors and outcome (Doctoral dissertation, Universiteit van Amsterdam [Host]).
  2. ↑ Hilton-Jones, David (2011). “Observations on the classification of the inflammatory myopathies”. La Presse Médicale. 40 (4): e199–e208. doi:10.1016/j.lpm.2010.10.035. ISSN 0755-4982.
  3. ↑ Leclair V, Lundberg IE (March 2018). “New Myositis Classification Criteria-What We Have Learned Since Bohan and Peter”. Curr Rheumatol Rep. 20 (4): 18. doi:10.1007/s11926-018-0726-4. PMC 5857275. PMID 29550929.
  4. ↑ Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O’Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG (December 2017). “2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups”. Ann. Rheum. Dis. 76 (12): 1955–1964. doi:10.1136/annrheumdis-2017-211468. PMID 29079590.
  5. ↑ Benveniste, Olivier; Léger, Jean-Marc (2011). “Inflammatory or necrotizing myopathies, myositides and other acquired myopathies, new insight in 2011”. La Presse Médicale. 40 (4): e197–e198. doi:10.1016/j.lpm.2011.02.002. ISSN 0755-4982.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]